Meningococcal Disease Vaccine Global Market Report 2025

The meningococcal disease vaccine market size has grown rapidly in recent years. It will grow from$2.37 billion in 2024 to $2.62 billion in 2025 at a compound annual growth rate (CAGR) of 10.4%. The growth during the historic period can be attributed to enhanced vaccine manufacturing capabilities, the establishment of global health partnerships, incorporation into national immunization programs, an increase in meningococcal disease cases, and intensified efforts by various organizations.

The meningococcal disease vaccine market size is expected to see rapid growth in the next few years. It will grow to$3.83 billion in 2029 at a compound annual growth rate (CAGR) of 10%. The growth projected for the forecast period can be attributed to rising awareness of preventive healthcare, the expansion of target age groups, the entry of new market participants, stockpiling initiatives by governments and health agencies in preparation for potential outbreaks, and increasing public education efforts. Key trends expected during this period include advancements in vaccine technology, the development of multivalent, conjugate, and protein-based vaccines, global trends in travel and migration, increased research and development in mRNA technology, and innovations in thermostable vaccine formulations.

The growth of the meningococcal disease vaccine market is being driven by the rise in government immunization programs. These programs are public health initiatives that provide free or affordable vaccines to protect populations against infectious diseases. The expansion of these programs stems from a stronger focus on disease prevention and reducing the burden on healthcare systems through widespread vaccination efforts. By increasing access to vaccines and boosting immunization rates, these programs help raise public awareness and lower disease incidence. They also generate demand through vaccination mandates and public health campaigns. For example, in April 2024, the Pan American Health Organization (PAHO), a US-based specialized agency, launched the 22nd Vaccination Week in the Americas (VWA) under the theme “Engage now to protect your future. GetVax.” The campaign aimed to boost vaccine coverage, particularly in underserved communities, by administering over 65 million doses. The initiative targeted misinformation and improved vaccine access through community outreach and customized campaigns. As a result, growing government immunization efforts are fueling the expansion of the meningococcal disease vaccine market.

Leading players in the meningococcal disease vaccine market are focusing on the development of advanced vaccines, such as pentavalent formulations, to broaden serogroup protection, simplify vaccination schedules, and enhance disease prevention. A pentavalent meningococcal vaccine offers immunization against five major serogroups of Neisseria meningitidis in a single dose, minimizing the need for multiple injections and improving vaccine compliance. For instance, in October 2023, Pfizer Inc., a US-based biopharmaceutical firm, received FDA approval for PENBRAYA, the first and only vaccine approved for preventing meningococcal disease in individuals aged 10 to 25 years. This groundbreaking vaccine merges elements from two existing vaccines, Trumenba and Nimenrix, to safeguard against the five most common serogroups (A, B, C, W, and Y) of Neisseria meningitidis, which are responsible for the majority of invasive meningococcal disease (IMD) cases worldwide. PENBRAYA marks a major leap in disease prevention by offering the widest serogroup coverage among U.S.-available vaccines and potentially reducing the total number of required doses for complete protection.

In September 2023, Biovac, a biopharmaceutical company based in South Africa, joined forces with EuBiologics Co. Ltd. to enhance Africa’s capacity for vaccine innovation and self-reliance. This collaboration is focused on technology transfer and the local production of a pentavalent meningococcal conjugate vaccine in Africa. The initiative seeks to meet urgent healthcare demands in the meningitis belt and promote regional vaccine manufacturing capabilities. EuBiologics Co., Ltd., based in South Korea, specializes in the production of pentavalent meningococcal conjugate vaccines.

Major players in the meningococcal disease vaccine market are Pfizer Inc., Merck & Co. Inc., Sanofi SA, Novartis AG, GlaxoSmithKline plc, Hualan Biological Engineering Inc., Beijing Tiantan Biological Products Corporation Limited, Serum Institute of India Pvt. Ltd., Walvax Biotechnology Co. Ltd., Incepta Pharmaceuticals Ltd., CanSino Biologics Inc., EuBiologics Co. Ltd., Biovac Institute, Shantha Biotech, Bio-Manguinhos, Biomed Pvt. Ltd., Chengdu Kanghua Biological Products Co. Ltd., Zhejiang Tianyuan Bio-Pharmaceutical Co. Ltd., Finlay Institute of Vaccines, and Immunopreparat.

North America was the largest region in the meningococcal disease vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in meningococcal disease vaccine report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the meningococcal disease vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The meningococcal disease vaccine is designed to protect against meningococcal disease, a severe bacterial infection caused by Neisseria meningitidis. This illness can result in meningitis, which is the inflammation of the membranes surrounding the brain and spinal cord, as well as septicemia, a serious bloodstream infection both of which can be life-threatening.

There are several main types of meningococcal vaccines conjugate vaccines, polysaccharide vaccines, recombinant vaccines, and live attenuated vaccines. Conjugate vaccines work by linking bacterial sugars to proteins, thereby enhancing the immune response and providing effective protection against serogroups A, C, W, and Y. These vaccines are particularly recommended for adolescents and individuals at higher risk. They are available for a range of age groups, including infants, children, adults, and the elderly, and are used for various purposes such as routine prevention, post-exposure prophylaxis, travel immunization, and in response to outbreaks. Distribution channels include hospital pharmacies, retail pharmacies, online pharmacies, and others, with end-users comprising hospitals, specialty clinics, home care services, and additional healthcare settings.

The meningococcal disease vaccines market research report is one of a series of new reports that provides meningococcal disease vaccines market statistics, including the meningococcal disease vaccines industry global market size, regional shares, competitors with the meningococcal disease vaccines market share, detailed meningococcal disease vaccines market segments, market trends, and opportunities, and any further data you may need to thrive in the meningococcal disease vaccines industry. This meningococcal disease vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The meningococcal disease vaccine market consists of sales of protein-based vaccines, outer membrane vesicle (OMV) vaccines, and multicomponent vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.